MedTrace Logo

The Effect of Empagliflozin on Glucose Metabolism, Weight, Blood Pressure and Cardiac Function (NT-proBNP) Should be Investigated

NCT03131232 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2017-04-27

No results posted yet for this study

Summary

In summary, the registry should provide novel insight into potential mechanisms of cardiovascular risk reduction in patients treated with Empagliflozin with an indication of intensified glucose lowering therapy based on their HbA1c level.

Conditions

  • Diabetes Mellitus, Type 2

Sponsors & Collaborators

  • RWTH Aachen University

    lead OTHER

Principal Investigators

  • Dirk DM Müller Wieland, Scientific Director · Coordination Center for Clinical Study

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-10
Primary Completion
2017-08-01
Completion
2017-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03131232 on ClinicalTrials.gov